Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Doxorubicin Hydrochloride, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide, and Dexamethasone Prior to Scheduled Stem-Cell Transplant in Newly Diagnosed Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.
Read Article
Lenalidomide Induction and Maintenance Therapy for Transplant-Eligible Myeloma Patients: Results of the Myeloma XI Study
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.
Read Article
Impact of t(11;14) on Outcomes in African American and Non–African American Patients with NDMM: Connect MM Registry
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.
Read Article
Pembrolizumab plus Lenalidomide and Low-Dose Dexamethasone for RRMM: Efficacy and Biomarker Analyses
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T-Cell Therapy for RRMM: Updated Results
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Pomalidomide + Low-Dose Dexamethasone after Lenalidomide-Based Second-Line Treatment in Patients with RRMM: Analysis of Progression-Free Survival by Level of Disease Control
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
CALGB/ECOG 100104 (Alliance) Study: Lenalidomide versus Placebo Maintenance After Stem-Cell Transplant for Patients with MM—OS and PFS Adjusted for Treatment Crossover
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover.
Read Article
Impact of Post-ASCT Maintenance Therapy on Outcomes in Patients with NDMM Using the Large, Prospective Community-Based Connect MM Registry
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM).
Read Article
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM: Efficacy and Safety Update (POLLUX)
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
An update on the POLLUX study has shown that daratumumab, lenalidomide, and dexamethasone improves efficacy outcomes in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Phase 3 ELOQUENT-2 Study: Extended 4-Year Follow-Up of Elotuzumab plus Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
The 4-year follow-up of the ELOQUENT-2 study examining elotuzumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) shows sustained safety and efficacy results.
Read Article
Page 16 of 44
13
14
15
16
17
18
19
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma